Stanford



Jane Antony

Postdoctoral Research Fellow, Stem Cell Biology and Regenerative Medicine

Bio

HONORS AND AWARDS

- Dean’s Postdoctoral Fellowship, Stanford University (July 2018 - June 2019)
- NGS Graduate Scholarship, National University of Singapore - Imperial College London (August 2012 - July 2016)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Postdoctoral member, American Society for Cell Biology (ASCB) (2018 - present)
- Member, TEMTIA, The EMT International Association (2018 - present)
- Associate member, American Association for Cancer Research (2018 - present)
- Young Investigator membership, Eauropean Association for Cancer Research (EACR) (2018 - present)

PROFESSIONAL EDUCATION

- Doctor of Philosophy, National University Of Singapore (2017)
- Bachelor of Engineering, National University Of Singapore (2012)
- Doctor of Philosophy, Imperial College of Science, Technology & Medicine (2017)

PATENTS

- Michael F. Clarke, Neethan A. Lobo, Maider Zabala Ugalde, Jane Antony. "United States Patent 103182-1086502-000501US COMPOSITIONS AND METHODS FOR MODULATING LEFTY AND BMP PROTEINS", Chan Zuckerberg Biohub, The Board Of Trustees Of The Leland Stanford Junior University

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

Although varying degrees of progress has been made to treat the heterogenous subtypes of breast cancers, metastasis and recurrence remains a major cause of breast cancer-related deaths. My research focuses on drivers of tumor growth and testing new targets for these breast cancers to prevent metastasis and recurrence; specifically, profiling and validating genes enriched in the self-renewing tumorigenic compartment.

LAB AFFILIATIONS

- Michael Clarke, The Clarke Lab (9/1/2017)

Publications

PUBLICATIONS

- **Epithelial-to-mesenchymal transition: Lessons from development, insights into cancer and the potential of EMT-subtype based therapeutic intervention.** *Physical biology*

Antony, J., Thiery, J. P., Huang, R. Y.
2019

- **Usp16 modulates Wnt signaling in primary tissues through Cdkn2a regulation.** *Scientific reports*
  Adorno, M., di Robilant, B. N., Sikandar, S. S., Acosta, V. H., Antony, J., Heller, C. H., Clarke, M. F.
  2018; 8 (1): 17506

- **Synergistic inactivation of AXL: a (cross)road to cure ovarian cancer?** *EMBO reports*
  Zurzolo, C.
  2018

- **The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer** *EMBO Reports*
  Antony, J., Zanini, E., Kelly, ., Tan, T. Z., Karali, E., Alomary, M., Jung, Y., Nixon, K., Cunnea, P., Fotopoulou, C., Paterson, A., Roy#Nawathe, S., Mills, et al
  2018

- **The Tumor-Suppressor Protein OPCML Potentiates Anti-EGFR- and Anti-HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer** *MOLECULAR CANCER THERAPEUTICS*
  Zanini, E., Louis, L. S., Antony, J., Karali, E., Okon, I. S., Mckie, A. B., Vaughan, S., El-Bahrawy, M., Stebbing, J., Recchi, C., Gabra, H.
  2017; 16 (10): 2246–56

- **AXL-Driven EMT State as a Targetable Conduit in Cancer** *CANCER RESEARCH*
  Antony, J., Huang, R.
  2017; 77 (14): 3725–32

- **Targeting the AXL signaling pathway in ovarian cancer** *MOLECULAR & CELLULAR ONCOLOGY*
  Huang, R., Antony, J., Tan, T., Tan, D.
  2017; 4 (2): e1263716

- **The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer** *SCIENCE SIGNALING*
  Antony, J., Tan, T., Kelly, Z., Low, J., Choolani, M., Recchi, C., Gabra, H., Thiery, J., Huang, R.
  2016; 9 (448): ra97

- **New twists in the AXL(e) of tumor progression** *SCIENCE SIGNALING*
  Halmos, B., Haura, E. B.
  2016; 9 (448): fs14

- **Sustained Gas6/AXL signaling network in the mes subtype of ovarian cancer as a molecular subtype specific therapeutic target.**
  Huang, R., Antony, J., Tan, T., Kelly, Z., Gabra, H., Recchi, C., Thiery, J.
  AMER SOC CLINICAL ONCOLOGY.2016